Shed Safety, Regulation & Compliance Posture

What Is Shed and How Does It Operate?

Shed is a direct-to-consumer telehealth company that connects patients with licensed prescribers who can order compounded semaglutide or tirzepatide for weight management. The company markets itself as a lower-cost alternative to brand-name GLP-1 medications like Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide).

The business model follows a pattern common among dozens of telehealth weight-loss startups that emerged between 2022 and 2025. Patients complete an intake questionnaire, a provider reviews the submission, and if appropriate, a prescription is sent to a partnered compounding pharmacy. The medication ships directly to the patient. Shed does not manufacture drugs itself. It acts as an intermediary between the patient, the prescriber, and the compounder.

This distinction matters. The safety of the medication a patient receives depends almost entirely on the compounding pharmacy's quality controls, not on Shed's website design or marketing language. The FDA has repeatedly warned that compounded drugs do not undergo the same premarket review as FDA-approved products, meaning patients assume a different risk profile compared to using commercially manufactured semaglutide [1].

Compounded GLP-1s: The Regulatory Framework

Compounded semaglutide exists in a specific regulatory gray zone. The FDA permits compounding under two pathways. Section 503A of the Federal Food, Drug, and Cosmetic Act covers traditional pharmacies filling patient-specific prescriptions. Section 503B covers outsourcing facilities that can produce larger batches without individual prescriptions but must register with the FDA and follow current good manufacturing practices (cGMP) [2].

The critical question for any Shed customer: does the pharmacy filling your prescription operate under 503A or 503B? A 503B outsourcing facility undergoes FDA inspection and must report adverse events. A 503A pharmacy answers primarily to its state board of pharmacy. The difference in oversight is substantial.

In 2023, the FDA placed semaglutide on its drug shortage list, which temporarily allowed compounders to produce copies of the drug under section 503A and 503B. When Novo Nordisk resolved supply issues for certain dose strengths, the FDA moved to remove semaglutide from the shortage list in late 2024, creating legal uncertainty for compounders [3]. A federal court ruling in early 2025 temporarily blocked the FDA's removal of semaglutide from the shortage list in certain jurisdictions, but the regulatory status remains contested.

For consumers using Shed, this means the legal basis for the compounded product you receive could shift. That alone is not a safety issue, but it signals instability in the supply chain.

Sterility and Potency: The Real Safety Questions

The most pressing safety concern with any compounded injectable is whether the product is sterile, accurately dosed, and free of contaminants. These are not theoretical risks.

In 2024, the FDA issued warnings about adverse events linked to compounded semaglutide, including reports of dosing errors that led to hypoglycemia and severe gastrointestinal symptoms [4]. Some compounders were found producing semaglutide salt forms (such as semaglutide sodium) that have not been studied in clinical trials and may have different pharmacokinetic properties than the acetate form used in Wegovy [5].

A 2023 analysis published in JAMA Network Open examined compounded peptide products obtained from multiple pharmacies and found that 10 of 18 samples (55.6%) failed to meet labeled potency claims, with some containing as little as 60% of the stated dose [6]. This variability means a patient could receive a subtherapeutic dose one month and an excessive dose the next.

Shed does not publicly disclose which compounding pharmacies it partners with, making it difficult for consumers to independently verify the facility's inspection history or compliance record. The FDA maintains a searchable database of registered 503B outsourcing facilities that consumers can check, but only if they know the pharmacy name [2].

How Shed's Prescribing Model Compares to Clinical Guidelines

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends GLP-1 receptor agonists as first-line pharmacotherapy for adults with a BMI of 30 or greater, or 27 or greater with weight-related comorbidities [7]. The guideline specifies that treatment should include baseline labs (HbA1c, lipid panel, hepatic function), structured follow-up at 4 to 12 week intervals, and dose titration based on tolerability.

Shed's intake process, based on publicly available information, relies on a questionnaire-based evaluation. Some telehealth models in this space have been criticized for inadequate screening. A 2024 study in Annals of Internal Medicine found that 3 of 10 telehealth weight-loss platforms prescribed GLP-1 medications to standardized patients who disclosed contraindications, including a history of medullary thyroid carcinoma, a black-box contraindication for semaglutide [8].

Whether Shed specifically screens for MTC family history, multiple endocrine neoplasia type 2 (MEN2), or a personal history of pancreatitis is not independently verified. The FDA labeling for Wegovy and Ozempic includes a boxed warning about thyroid C-cell tumors based on rodent studies, and the prescribing information states the drug is contraindicated in patients with a personal or family history of MTC or MEN2 [9].

Dr. Caroline Apovian, a co-author of the Endocrine Society guideline, has stated: "Any platform prescribing GLP-1 medications without verifying thyroid cancer history and pancreatitis risk is not meeting the standard of care" [7]. This applies to Shed and every competitor in the space.

Adverse Event Reporting and Post-Market Surveillance

FDA-approved medications like Wegovy come with strong pharmacovigilance infrastructure. Novo Nordisk must report adverse events to the FDA, and the FAERS (FDA Adverse Event Reporting System) database captures post-market safety signals. The STEP trial program, which included over 15,000 patients across multiple randomized controlled trials, established a well-characterized safety profile: nausea in 44% of participants, vomiting in 24.8%, and diarrhea in 30% at the 2.4 mg dose in STEP-1 (N=1,961) [10].

Compounded products have no equivalent surveillance infrastructure. 503A pharmacies have no federal adverse event reporting requirement. While 503B facilities must report, enforcement varies. If a patient receiving compounded semaglutide from Shed experiences a serious adverse reaction, the event may never reach the FDA's database.

This gap matters because the STEP trials used a specific formulation manufactured under cGMP conditions. Compounded versions may differ in excipients, pH, osmolality, and semaglutide salt form. A product that looks similar on paper could behave differently in the body.

Shed vs. FDA-Approved Alternatives: A Direct Comparison

The primary value proposition of Shed and similar platforms is price. Wegovy carries a list price of approximately $1,349 per month without insurance. Zepbound lists at approximately $1,059 per month [11]. Shed's compounded alternatives typically range from $199 to $499 per month.

That price difference is real, and for patients without insurance coverage for anti-obesity medications, it can be the deciding factor. A 2024 KFF survey found that only 18% of large employer plans covered GLP-1 medications specifically for weight loss [12].

But cost savings must be weighed against known tradeoffs. FDA-approved products guarantee consistent potency within 90% to 110% of labeled strength, confirmed through batch testing and FDA inspection. They carry established safety data from thousands of trial participants. They are supported by patient assistance programs and savings cards that can reduce out-of-pocket costs to as low as $0 to $25 per month for commercially insured patients [11].

Compounded products offer none of these guarantees. The savings are real. So are the uncertainties.

What to Verify Before Using Shed

Patients considering Shed should ask specific questions before starting treatment. Request the name of the compounding pharmacy and verify its registration status on the FDA's 503B database or the relevant state board of pharmacy website. Ask whether the pharmacy has a recent FDA inspection report (Form 483) and what the findings were [2].

Confirm that your prescriber will review baseline labs before prescribing. At minimum, this should include a metabolic panel, HbA1c, and thyroid function tests. The American Association of Clinical Endocrinology (AACE) recommends screening for obstructive sleep apnea and cardiovascular risk factors before initiating GLP-1 therapy [13].

Ask about the specific semaglutide salt form used. The FDA has specifically cautioned against semaglutide sodium, noting it is not the same active ingredient as in approved products [4]. If the pharmacy cannot or will not disclose this information, that is a red flag.

Verify that follow-up appointments are included in the subscription and that dose titration follows the standard schedule: 0.25 mg weekly for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, then 2.4 mg maintenance, per the Wegovy prescribing information [9]. Skipping titration steps to accelerate weight loss increases the risk of severe gastrointestinal side effects and rare complications like pancreatitis.

The Broader Regulatory Picture for Telehealth Compounding

The DEA and state medical boards have tightened scrutiny of telehealth prescribing since the end of the COVID-19 public health emergency. The Ryan Haight Act requires at least one in-person evaluation before prescribing controlled substances via telehealth, though GLP-1 medications are not scheduled drugs and are currently exempt from this requirement [14].

State-level regulation varies widely. Some states require synchronous (live video) consultations for new prescriptions, while others permit fully asynchronous (questionnaire-only) models. California's Medical Board and the Texas Medical Board have both issued guidance emphasizing that asynchronous prescribing must still meet the standard of care for an adequate patient evaluation [15].

The FTC has also entered the arena. In 2024, the agency issued warning letters to telehealth companies making unsupported efficacy claims about compounded weight-loss products, including claims of equivalence to FDA-approved medications. Whether Shed has received such a letter is not publicly confirmed, but consumers should be skeptical of any marketing that implies compounded semaglutide is "the same" as Wegovy [1].

The SELECT trial (N=17,604) demonstrated that FDA-approved semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in adults with overweight or obesity and established cardiovascular disease [16]. No compounded semaglutide product has been studied in a cardiovascular outcomes trial. The clinical evidence supporting cardiovascular benefit applies exclusively to the manufactured, FDA-approved formulation.